MannKind (MNKD) Jumps On FDA Approval Of Furoscix ReadyFlowThe FDA has approved Furoscix ReadyFlow, a furosemide injection designed to treat edema (swelling caused by excess fluid trapped in the body’s tissue) in adults with heart failure or chronic kidney disease.The product is notable for being the first autoinjector delivering IV-equivalent exposure, potentially allowing for quicker symptom relief and reducing the need for emergency interventions.Furoscix ReadyFlow provides a full 80 mg/mL dose in a simple, patient-friendly format administered in under 10 seconds.Heart failure affects approximately 6.7 million adults in the United States and is projected to increase to more than 8 million by 2030.Concurrently, the biopharmaceutical company announced a private placement financing of approximately $50 million.MannKind will use the proceeds for general corporate purposes, including funding the $45 million contingent value rights payment triggered by the recent FDA approval of Furoscix ReadyFlow.MNKD Technical Analysis: Key Levels And MomentumMannkind’s stock is currently trading at $4.20, which is 2.5% above its 20-day simple moving average (SMA) of $4.11 and 11.7% above its 50-day SMA of $3.77.The moving average convergence divergence (MACD) is below its signal line, indicating that momentum is fading, suggesting that the recent price increase may not be sustainable unless the stock can regain upward momentum.